TICKERNERD
Menu
EWEWHealthcare · Medical Devices

EW Stock Forecast: Edwards Lifesciences Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$92
−1.04% on the day

The 28 Wall Street analysts covering Edwards Lifesciences Corp. hold a median 12-month price target of $102 — +10.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$53.4B
Ticker Nerd rank
91 / 100
Median analyst target
$102
Analysts covering
28
Total return, dividends reinvested
1W
+2.1%
1M
+1.7%
YTD
+7.4%
1Y
+17.2%
From 52W high
−3.8%
From 52W low
+26.1%
$73
$95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Edwards Lifesciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
84
Quality
82
Growth
80
Value
79
Issuance
77
Momentum
74
Revisions
70
Accruals
70
Size
5

Volatility (84): The share price has been relatively steady.

Accruals (70): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26EWHigh $110Median $102Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
21 Buy7 Hold0 Sell
Low $84Median $102High $110

The green dot is the last close — the median target sits +10.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 July 2026UBSAssumesBuy$110
25 July 2026Leerink PartnersUpgradeOutperform—
24 July 2026JP MorganMaintainsOverweight—
24 July 2026JP MorganMaintainsOverweight$100 → $105
24 July 2026Leerink PartnersUpgradeOutperform$87 → $101
24 July 2026Piper SandlerReiteratesOverweight$100 → $101
24 July 2026Piper SandlerReiteratesOverweight—
16 July 2026Truist SecuritiesMaintainsHold—
16 July 2026Truist SecuritiesMaintainsHold$90 → $95
15 July 2026MizuhoMaintainsOutperform$100 → $105
15 July 2026MizuhoMaintainsOutperform—
13 July 2026RBC CapitalMaintainsOutperform—
13 July 2026RBC CapitalMaintainsOutperform$100 → $110
8 July 2026CitigroupMaintainsBuy$101 → $110
8 July 2026CitigroupMaintainsBuy—
6 July 2026Evercore ISI GroupMaintainsOutperform$93 → $100
6 July 2026Evercore ISI GroupMaintainsOutperform—
30 June 2026BTIGMaintainsBuy—
16 June 2026RBC CapitalReiteratesOutperform—
2 June 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EW appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
5
Analysts cutting
11
Fundamentals

Edwards Lifesciences Corp. (EW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
54.9×

Cheaper than 14% of US stocks

Price / sales
8.2×

Cheaper than 17% of US stocks

Price / book
5.0×

Cheaper than 22% of US stocks

EV / EBITDA
25.0×

Cheaper than 12% of US stocks

Growth & margins
Revenue growth (YoY)
13.6%

Higher than 60% of US stocks

Earnings growth (YoY)
−27.4%

Higher than 16% of US stocks

Gross margin
77.5%

Higher than 89% of US stocks

Operating margin
29.8%

Higher than 87% of US stocks

Net margin
15.4%

Higher than 78% of US stocks

Returns & dividend
Return on equity
9.2%

Higher than 61% of US stocks

Return on assets
8.4%

Higher than 89% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
EWEdwards Lifesciences Corp.$53.4B
91
BSXBoston Scientific Corp.$76.6B
57
DXCMDexCom, Inc.$35.3B
98
GEHCGE Healthcare Technologies, Inc.$33.6B
64
MDTMedtronic PLC$116.1B
83
STESTERIS Plc (Ireland)$23.0B
87
SYKStryker Corp.$130.4B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Edwards Lifesciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EW news & analysis

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Zacks Investment Research · 14 Aug 2026neutral

Zacks Investment Research reported that Edwards Lifesciences has accelerating structural heart growth and stronger leverage, but faces a premium valuation that reduces room for execution setbacks.

Why it matters — EW watchers would care because the article highlights both the company's growth strengths and the risk that its high valuation leaves little tolerance for any operational missteps.

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Zacks Investment Research · 13 Aug 2026positive

Edwards Lifesciences shares rose 14% over three months, reflecting broad structural-heart growth, according to a Zacks Investment Research report. The report notes that the company's premium valuation raises the bar for execution.

Why it matters — EW watchers should note that the recent share-price rally underscores growth in structural-heart business, while the premium valuation heightens expectations for the company's execution.

Aristotle Value Equity WM Q2 2026 Portfolio Performance

Seeking Alpha · 6 Aug 2026neutral

Aristotle Capital's Value Equity WM Composite posted a 4.36% gross (3.85% net) total return for Q2 2026. Corteva and Motorola Solutions were among the largest detractors during the quarter.

Why it matters — The report does not mention Edwards Lifesciences, so it provides no direct information on the company and holds no distinct implications for EW watchers.

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Zacks Investment Research · 30 July 2026neutral

Zacks Investment Research noted that recent movements in the options market suggest investors should pay close attention to Edwards Lifesciences stock.

Why it matters — Options market activity can signal expectations for a stock's near-term direction, so EW watchers may want to monitor for potential volatility.

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Benzinga · 24 July 2026positive

Edwards Lifesciences reported second-quarter results that surpassed Wall Street estimates and raised the low end of its full-year revenue guidance, causing its stock to rise on Friday.

Why it matters — A guidance raise and earnings beat signal continued operational strength for Edwards, reinforcing a bullish outlook among analysts covering the medtech sector.

FAQ

Frequently asked questions about EW stock

What is the EW stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Edwards Lifesciences Corp. have a median 12-month price target of $102, with estimates ranging from $84 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EW stock a buy right now?

Of the 28 analysts covering Edwards Lifesciences Corp., 21 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edwards Lifesciences Corp. 91 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EW?

As at 13 Aug 2026, Edwards Lifesciences Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).

Will EW stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +10.8% from the last close, and Ticker Nerd's factor model ranks Edwards Lifesciences Corp. 91 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EW stock forecast for 2030?

No analyst covering Edwards Lifesciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $110 over the next 12 months.

How has EW stock performed over the past year?

Edwards Lifesciences Corp. returned +17.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edwards Lifesciences Corp. do?

Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and advanced cardiovascular care. The company develops and markets transcatheter heart valve replacement systems, surgical heart valves, and repair technologies used in procedures for aortic, mitral, and tricuspid valve conditions.

What is the latest news on EW?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?". Zacks Investment Research reported that Edwards Lifesciences has accelerating structural heart growth and stronger leverage, but faces a premium valuation that reduces room for execution setbacks.

Company

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and advanced cardiovascular care. The company develops and markets transcatheter heart valve replacement systems, surgical heart valves, and repair technologies used in procedures for aortic, mitral, and tricuspid valve conditions. Its portfolio also includes hemodynamic monitoring solutions that help clinicians assess cardiovascular function in hospital settings. Edwards Lifesciences serves hospitals, cardiac specialists, and healthcare systems across major global markets, with products designed for both minimally invasive and surgical applications. Headquartered in Irvine, California, Edwards Lifesciences plays a significant role in the cardiovascular device market through specialized therapies and diagnostic tools used in the treatment of complex heart disease.

CEO Mr. Bernard J. Zovighian · 16,000 employees · United States · https://www.edwards.com